| Name | Title | Contact Details |
|---|
Acelity is a global market leader in advanced wound therapeutics and regenerative medicine, offering innovative solutions from the hospital to home that improve the lives of patients in more than 80 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. We are the undisputed leader in negative pressure wound therapy, the number one provider of regenerative tissue products used for breast reconstruction and hernia repair, and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with more than 5,800 employees around the globe.
Athena Health Care Systems is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Athena Health Care Systems is based in Farmington, CT. You can find more information on Athena Health Care Systems at www.athenahealthcare.com
CGIT is a Quincy, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Outer Cape Health Services -Wellfleet Health Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Wellfleet, MA. To find more information about Outer Cape Health Services -Wellfleet Health Center, please visit www.outercape.org
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.